Yasuhiro Koh

10PUBLICATIONS
14CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsLiquid biopsiesCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Apr 05, 2025
Circulating Tumour DNA in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer and Early Disease Progression After First-Line Osimertinib Treatment: The ELUCIDATOR Multicentre Prospective Observational Study.

Akihiro Tamiya, Yasuyuki Mizumori, Mitsuo Osuga

|Mar 08, 2024
Mannitol versus furosemide in patients with thoracic malignancies who received cisplatin-based chemotherapy using short hydration: A randomized phase II trial.

Eriko Murakami, Hiroaki Akamatsu, Shunsuke Teraoka

|Jun 28, 2022
Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L).

Hiroaki Akamatsu, Shunsuke Teraoka, Shinkichi Takamori

|Jun 02, 2021
Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.

Mio Ikeda, Yasuhiro Koh, Shunsuke Teraoka

|Oct 21, 2020
CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50.

Yuichi Ozawa, Yuhei Harutani, Jun Oyanagi

|Feb 06, 2020
Impact of somatic mutations on prognosis in resected non-small-cell lung cancer: The Japan Molecular Epidemiology for lung cancer study.

Akihiro Tamiya, Yasuhiro Koh, Shun-Ichi Isa

Pageof 2

Frequent Collaborators

3 joint publications

Hiroaki Akamatsu

3 joint publications

Yuichi Ozawa

2 joint publications

Akihiro Tamiya

2 joint publications

Nobuyuki Yamamoto